B6.129-B2mtm1Unc H2-Ab1b-tm1Doi/DoiOrl
Status | Available to order |
EMMA ID | EM:00030 |
International strain name | B6.129-B2mtm1Unc H2-Ab1b-tm1Doi/DoiOrl |
Alternative name | beta2m°, Abeta°(MHC) |
Strain type | Targeted Mutant Strains : Knock-out |
Allele/Transgene symbol | H2-Ab1b-tm1Doi, B2mtm1Unc |
Gene/Transgene symbol | H2-Ab1, B2m |
Information from provider
Provider | Diane MATHIS |
Provider affiliation | LGME Universite |
Phenotypic information | Double-mutant mice deficient in products of beta-2 microglobulin, and histocompatibility 2, class II antigen A, beta 1 (MHC class I and II) genes. Obtained by crossing of strains carrying the B2m and H2-Ab1 gene mutations. They generally show a deficiency in T lymphocytes (CD4 and CD8 compartments). |
Breeding history | 129P2/OlaHsd and 129S2/SvPas ES cells; 9 generations of backcross to C57BL/6, then intercross. |
References |
|
Information from EMMA
Archiving centre | Institut de Transgenose, INTRAGENE, Orléans, France |
Disease and phenotype information
Orphanet associated rare diseases, based on orthologous gene matching
- Immunodeficiency by defective expression of MHC class I / Orphanet_34592
- Variant ABeta2M amyloidosis / Orphanet_314652
IMPC phenotypes (gene matching)
MGI phenotypes (allele matching)
- decreased level of surface class I molecules / MGI
- decreased CD8-positive, alpha-beta T cell number / MGI
- decreased IgG level / MGI
- abnormal pancreas morphology / MGI
- decreased susceptibility to bacterial infection / MGI
- increased IgM level / MGI
- decreased susceptibility to autoimmune diabetes / MGI
- decreased circulating serum albumin level / MGI
- increased T-helper 1 cell number / MGI
- abnormal interleukin level / MGI
- abnormal tumor necrosis factor level / MGI
- increased susceptibility to infection induced morbidity/mortality / MGI
- absent CD8-positive, alpha-beta T cells / MGI
- abnormal pancreatic beta cell morphology / MGI
- abnormal T cell number / MGI
- insulitis / MGI
MGI phenotypes (gene matching)
- absent CD8-positive, alpha-beta T cells / MGI
- decreased IgG level / MGI
- decreased level of surface class I molecules / MGI
- abnormal pancreas morphology / MGI
- decreased susceptibility to bacterial infection / MGI
- abnormal CD8-positive, alpha-beta cytotoxic T cell morphology / MGI
- increased IgM level / MGI
- insulitis / MGI
- abnormal lateral geniculate nucleus morphology / MGI
- decreased susceptibility to autoimmune diabetes / MGI
- decreased susceptibility to parasitic infection / MGI
- abnormal cytotoxic T cell physiology / MGI
- abnormal pancreatic beta cell morphology / MGI
- decreased circulating serum albumin level / MGI
- hemochromatosis / MGI
- abnormal T cell number / MGI
- decreased CD8-positive, alpha-beta T cell number / MGI
- increased T-helper 1 cell number / MGI
- increased gamma-delta T cell number / MGI
- increased gamma-delta intraepithelial T cell number / MGI
- increased tumor necrosis factor secretion / MGI
- increased interleukin-3 secretion / MGI
- decreased interleukin-4 secretion / MGI
- abnormal interleukin level / MGI
- abnormal tumor necrosis factor level / MGI
- increased susceptibility to infection induced morbidity/mortality / MGI
- abnormal immune system morphology / MGI
- abnormal spleen morphology / MGI
- abnormal immune system cell morphology / MGI
- hemolytic anemia / MGI
- postnatal growth retardation / MGI
- abnormal immune system physiology / MGI
- abnormal humoral immune response / MGI
- decreased IgG level / MGI
- decreased IgM level / MGI
- autoimmune response / MGI
- reduced fertility / MGI
- premature death / MGI
- abnormal T cell differentiation / MGI
- no abnormal phenotype detected / MGI
- abnormal spleen periarteriolar lymphoid sheath morphology / MGI
- abnormal spleen marginal zone morphology / MGI
- abnormal dendritic cell physiology / MGI
- abnormal CD4-positive, alpha beta T cell morphology / MGI
- abnormal T cell physiology / MGI
- abnormal dendritic cell antigen presentation / MGI
- abnormal B cell physiology / MGI
- abnormal immunoglobulin level / MGI
- increased IgM level / MGI
- abnormal immune system organ morphology / MGI
- increased urine protein level / MGI
- abnormal cytokine secretion / MGI
- abnormal artery development / MGI
- abnormal response/metabolism to endogenous compounds / MGI
- absent CD4-positive, alpha beta T cells / MGI
- abnormal lymphocyte physiology / MGI
- insulitis / MGI
- increased anti-double stranded DNA antibody level / MGI
- increased anti-single stranded DNA antibody level / MGI
- increased anti-erythrocyte antigen antibody level / MGI
- decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
- decreased susceptibility to experimental autoimmune myasthenia gravis / MGI
- decreased regulatory T cell number / MGI
- increased B cell number / MGI
- decreased susceptibility to parasitic infection / MGI
- increased susceptibility to parasitic infection / MGI
- abnormal level of surface class II molecules / MGI
- increased double-negative T cell number / MGI
- decreased susceptibility to autoimmune disorder / MGI
- cardiovascular system phenotype / MGI
- immune system phenotype / MGI
- abnormal CD4-positive, alpha-beta T cell physiology / MGI
- abnormal response to transplant / MGI
- increased CD4-positive, alpha beta T cell number / MGI
- decreased CD4-positive, alpha beta T cell number / MGI
- increased CD8-positive, alpha-beta T cell number / MGI
- decreased CD8-positive, alpha-beta T cell number / MGI
- decreased single-positive T cell number / MGI
- abnormal spleen B cell follicle morphology / MGI
- absent spleen germinal center / MGI
- decreased IgG1 level / MGI
- decreased tumor necrosis factor secretion / MGI
- decreased interleukin-12 secretion / MGI
- abnormal lymph node cell ratio / MGI
- abnormal neuron proliferation / MGI
Literature references
- Another view of the selective model of thymocyte selection.;Chan S H, Cosgrove D, Waltzinger C, Benoist C, Mathis D, ;1993;Cell;73;225-36; 8097430
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).